[Seite 64↓]

Anhang

Publikationsverzeichnis

Originalarbeiten

1. Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel PT. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1 overexpressing breast cancer cell lines. Oncogene. 2002;in press

2. Bosanquet, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel PT. Bax-Expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia. 2002;15:in press

3. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dörken B, Schmalz HG, Daniel PT, Henze G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia. 2001;15:1735-42

4. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, Daniel PT. Activation of Caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor ligand interaction and occurs downstream of Caspase-3. Blood. 2001;97:1378-87

5. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT. Analysis of p53/BAX/p16ink4a/CDKN2 in esophageal squamous cell carcinoma: High BAX and p16ink4a/CDKN2 identifies patients with good prognosis. J Clin Oncol. 2001;19:2272-81

6. Raisova M, Hossini A, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol. 2001;177:333-40

7. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne C-H, Hillebrand T, Daniel PT, Fong Y, Lorenz M. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol. 2001;27:80-7

8. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dörken B, Daniel PT. Bax-Expression in benign and malignant thyroid tumors: Dysregulation of wild type p53 is associated with a high BAX and p21 expression in thyroid carcinoma. Int J Cancer. 2001;92:805-11

9. Friedrich K, Wieder T, von Haefen C, Radetzki S, Schulze-Osthoff K, Jänicke R, Dörken B, Daniel PT. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cells with acquired drug resistance. Oncogene. 2001;20:2749-460

10. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Lück H-J, Wolff G, Dörken B, Daniel PT. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer. 2000;87:517-21

11. Raisova M, Bektas M, Wieder T, Daniel P, Eberle J, Orfanos CE, Geilen CC. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett. 2000;473:27-32

12. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B, Daniel PT. Relapse in childhood acute lymphoblastic leukemia is associated with decrease of Bax/Bcl-2- ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2000;14:1606-13

13. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dörken B, Bargou RC. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098-103.

14. Essmann F, Wieder T, Otto A, Muller EC, Dörken B, Daniel PT. GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. Biochem J. 2000;346:777-83

15. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17:1364-74

16. Daniel PT, Sturm I, Ritschel S, Friedrich K, Dörken B, Bendzko P, Hillebrand T. Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. Anal Biochem. 1999;266:110-5

17. Daniel PT, Scholz C, Essmann F, Westermann J, Pezzutto A, Dörken B. CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. Exp Hematol. 1999;27:1402-8

18. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dörken B, Brown R. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood. 1999;94:1100-7

19. Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dörken B. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer. 1998;77:973-7

20. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B, Pezzutto A. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood. 1998;92:4750-7

21. Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R, Dörken B. Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Eur J Immunol. 1997;27:1029-34

22. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dörken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol. 1997;159:3808-15

23. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dörken B. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer. 1996;67:138-41

24. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, Dörken B. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest. 1996;97:2651-9

25. Bargou RC, Wagener C, Bommert K, Arnold W, Daniel PT, Mapara MY, Grinstein E, Royer HD, Dörken B. Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J Exp Med. 1996;183:1205-13

26. Mapara MY, Weinmann P, Bommert K, Daniel PT, Bargou R, Dörken B. Involvement of NAK-1, the human nur77 homologue, in surface IgM- mediated apoptosis in Burkitt lymphoma cell line BL41. Eur J Immunol. 1995;25:2506-10

27. Lagresle C, Bella C, Daniel PT, Krammer PH, Defrance T. Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule. J Immunol. 1995;154:5746-56

28. Chlichlia K, Moldenhauer G, Daniel PT, Busslinger M, Gazzolo L, Schirrmacher V, Khazaie K. Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene. 1995;10:269-77

29. Blase L, Daniel PT, Koretz K, Schwartz-Albiez R, Moller P. The capacity of human malignant B-lymphocytes to disseminate in SCID mice is correlated with functional expression of the fibronectin receptor alpha 5 beta 1 (CD49e/CD29). Int J Cancer. 1995;60:860-6

30. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995;60:854-9

31. Bargou RC, Bommert K, Weinmann P, Daniel PT, Wagener C, Mapara MY, Dörken B. Induction of Bax-alpha precedes apoptosis in a human B lymphoma cell line: potential role of the bcl-2 gene family in surface IgM-mediated apoptosis. Eur J Immunol. 1995;25:770-5

32. Lucking-Famira KM, Daniel PT, Moller P, Krammer PH, Debatin KM. APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia. 1994;8:1825-33

33. Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol. 1994;152:5624-32

34. Coney LR, Daniel PT, Sanborn D, Dhein J, Debatin KM, Krammer PH, Zurawski VR, Jr. Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. Int J Cancer. 1994;58:562-7

35. Bargou RC, Mapara MY, Zugck C, Daniel PT, Pawlita M, Dohner H, Dörken B. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med. 1993;177:1257-68

36. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol. 1992;149:3166-73

37. Daniel PT, Holzschuh J, Berg PA. Sulfadoxine specific lymphocyte transformation in a patient with eosinophilic pneumonia induced by sulfadoxine-pyrimethamine (Fansidar). Thorax. 1989;44:307-9

38. Daniel PT, Holzschuh J, Berg PA. The pathogenesis of cianidanol-induced fever. Eur J Clin Pharmacol. 1988;34:241-7

39. Berg PA, Holzschuh J, Daniel PT, Becker EW, Jedrychowski A. Cefotaxime-induced allergic agranulocytosis in an acute attack of serologically atypical primary biliary cirrhosis. Dtsch Med Wochenschr. 1988;113:1478-81

40. Saal JG, Daniel PT, Berg PA. Indoprofen-induced aplastic anemia in active connective tissue disease detected by drug-specific lymphocyte transformation. Klin Wochenschr. 1986;64:481-5

Übersichtsarbeiten, Buchbeiträge

1. Daniel PT, Sturm I, Wieder T, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia. 2001;15:1022-32

2. Daniel PT. Dissecting the pathways to death. Leukemia. 2000;14:2035-44

3. Daniel PT, Dörken B. Natural born killers. Selbstmord Programme von Zellen liefern neue Ansätze für die Krebstherapie. Humboldt Spektrum. 2000;7:4-8

4. Daniel PT, Pezzutto A, Dörken B. Humoral immunotherapy and the use of monoclonal antibodies. In: Textbook of Malignant Haematology, ed. by Degos, l., Linch, D. C., and Löwenberg, B. , Martin Dunitz Ltd., London. 1999:425-46

5. Köhne CH, Daniel PT, Dörken B. The value of weekly high dose infusional 5-fluorouracil in the treatment of advanced colorectal cancer. Tumori. 1997;83:S56-60

6. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM. Regulation of apoptosis in the immune system. Curr Opin Immunol. 1994;6:279-89

7. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Bäumler C, Hellbardt S, Germer M, Peter ME, Debatin KM. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994;142:175-91

8. Dhein J, Behrmann I, Daniel PT, Debatin KM, Klas C, Moller P, Oehm A, Trauth BC, Walczak H, Krammer PH. APO-I-mediated apoptosis in normal and malignant lymphocytes. Biochem Soc Trans. 1994;22:598-600

9. Berg PA, Daniel P, Holzschuh J. Immunsystem. In: Pathophysiologie des Menschen. Ed: K. Hierholzer, R. F. Schmidt, VCH Verlagsgesellschaft, Weinheim. 1991:2.1-2.30

10. Krammer PH, Behrmann I, Bier V, Daniel P, Dhein J, Falk MH, Garcin G, Klas C, Knipping E, Lücking-Famira KM, Matzku S, Oehm A, Richards S, Trauth BC, Bornkamm GW, Falk W, Möller P, Debatin K-M. Apoptosis in the APO-1 system. In: F. Cope and D. Tomei (eds.), Apoptosis: the molecular basis of cell death. Cold Spring Harbor Laboratory Press. 1991:87-99

11. Berg PA, Daniel PT. Co-trimoxazole-induced hepatic injury--an analysis of cases with hypersensitivity-like reactions. Infection. 1987;15 Suppl 5:S259-64

12. Berg PA, Daniel PT, Brattig N. Immunologie und Nachweis medikamentöser Allergien. In: Manuale allergologicum. Ed: E. F. Fuchs und K. H. Schulz, Dustri Verllag, Deisenhofen. 1987:IV.11.1-3

13. Berg PA, Daniel PT, Holzschuh J, Brattig N. Drug hypersensitivity. Diagnosis and immunopathogenesis. Dtsch Med Wochenschr. 1987;113:65-73

Kongresspublikationen, Letters to the Editor

1. Daniel PT, Sturm I, Wolff G, Petrowsky H, Köhne CH, Hillebrand T, Dörken B, Lorenz M. Analysis of the p53/BAX pathway: Low Bax-Expression is a negative prognostic factor in patients with resected liver metastases of colorectal adenocarcinoma. Langenbecks Arch Chir. 1999;Suppl. 1:163-9

2. Daniel PT, Kroidl A, Cayeux S, Scholz C, Sturm I, Blankenstein T, Pezzutto A, Dörken B. Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis. Adv Exp Med Biol. 1998;451:265-76

3. Daniel PT, Scholz C, Westermann J, Dörken B, Pezzutto A. Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals. Adv Exp Med Biol. 1998;451:173-7

4. Koehne CH, Daniel P. Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma [letter; comment]. N Engl J Med. 1996;334:990-1; discussion 1-2

5. Daniel PT, Holzschuh J, Muller CE, Roth HJ, Berg PA. Inhibition of phytohemagglutinine-induced T lymphocyte proliferation by 6-(octadecyldithio)purine, a novel liposomal prodrug of 6- mercaptopurine. Arch Toxicol Suppl. 1989;13:179-82

6. Berg PA, Daniel PT. Effects of flavonoid compounds on the immune response. Prog Clin Biol Res. 1988;280:157-71

7. Daniel PT, Holzschuh J, Diao GJ, Berg PA. Interference of the flavonoid compound cianidanol with macrophage function and lymphocyte activating mechanisms. Prog Clin Biol Res. 1988;280:205-9

8. Daniel PT, Falcioni F, Berg AU, Berg PA. Influence of cianidanol on specific and non-specific immune mechanisms. Methods Find Exp Clin Pharmacol. 1986;8:139-45

9. Saal JG, Daniel PT, Berg PA, Waller HD. Indoprofen-induced aplastic anaemia in systemic lupus, diagnosed by lymphocyte transformation tests [letter]. Lancet. 1985;1:1450-1


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
28.09.2004